Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | CFTR | P13569 | 1/20 | 0.33 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11475394 | 0.83 | DDB1 (0.40) | DDB1CRBNCTRB1CYP19A1KMT2A | |
| SCHEMBL13210441 | 0.76 | DDB1 (0.57) | DDB1CRBNCTRB1CYP19A1KMT2A | |
| SCHEMBL8920951 | 0.75 | SRD5A1 (0.46) | DDB1CRBNCTRB1CFTRGOPC | |
| SCHEMBL11796468 | 0.74 | DDB1 (0.43) | DDB1CRBNCTRB1CYP19A1KMT2A | |
| SCHEMBL11475323 | 0.74 | MT-CO2 (0.46) | DDB1CRBNCTRB1KMT2ACFTR | |
| SCHEMBL8919532 | 0.71 | SLC18A3 (0.40) | DDB1CRBNCYP19A1SIGMAR1SLC18A3 | |
| SCHEMBL28926874 | 0.70 | DDB1 (0.40) | DDB1CRBNCTRB1CYP19A1KMT2A | |
| SCHEMBL361599 | 0.69 | DDB1 (0.48) | DDB1CRBNCTRB1KMT2ACFTR | |
| SCHEMBL8452389 | 0.68 | DDB1 (0.38) | DDB1CRBNKMT2ASMN1; SMN2TSHR | |
| SCHEMBL15874652 | 0.67 | SLC18A3 (0.51) | DDB1CRBNCTRB1TP53L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118108591-B | Method for preparing carboxylic acid by catalyzing ring opening of cyclic ketone compound through oxidation by using N-heterocyclic carbene | 兰州大学 | 2024-07-09 | — | — | CN | disclosed |
| CN-118108591-A | Method for preparing carboxylic acid by catalyzing ring opening of cyclic ketone compound through oxidation by using N-heterocyclic carbene | 兰州大学 | 2024-05-31 | — | — | CN | disclosed |
| EP-1399433-B1 | FLUOROPYRROLIDINES AS DIPEPTIDYL PEPTIDASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2007-08-22 | — | — | EP | disclosed |
| US-7183290-B2 | Fluoropyrrolidines as dipeptidyl peptidase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-27 | — | — | US | disclosed |
| US-20040242636-A1 | Enzyme inhibitors as antiinflammatory ageents for psoriasis, obesity | SMITHKLINE BEECHAM CORPORATION | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242636-A1 | Enzyme inhibitors as antiinflammatory ageents for psoriasis, obesity | DPP4, DPP7, DPP3 | DDB1 1799/4885CRBN 4455/4885CTRB1 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.